Avid Bioservices, Inc.
2642 Michelle Drive, Suite 200
Tustin
California
92780
United States
Tel: 714-508-6100
Fax: 714-439-1300
Website: http://www.avidbio.com/
About Avid Bioservices, Inc.
Avid Bioservices Inc., located in Tustin CA, is a dedicated contract development and manufacturing organization (“CDMO”) focused on development and CGMP manufacturing of biopharmaceuticals products derived from mammalian cell culture. Avid provides a comprehensive range of process development, high quality CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With over 28 years of experience producing monoclonal antibodies, enzymes, and recombinant proteins in batch, fed-batch, and perfusion modes, Avid's services include CGMP clinical and commercial product manufacturing, purification, release and stability testing as well as regulatory strategy, submission and support. Avid also provides a variety of process development activities, including cell culture and feed optimization, analytical methods development, and product characterization.
Stock Symbol: CDMO
Take a virtual 3D tour of our Myford North facility featuring our CGMP single-use drug substance manufacturing suite and quality control labs.
140 articles about Avid Bioservices, Inc.
-
Avid Bioservices Appoints Oksana Lukash as Vice President, People
11/16/2022
Avid Bioservices, Inc. today announced the appointment of Oksana Lukash, as vice president, people.
-
Avid Bioservices to Participate in the Credit Suisse 31st Annual Healthcare Conference
11/2/2022
Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that the company will participate in the Credit Suisse 31st Annual Healthcare Conference.
-
Avid Bioservices to Participate in RBC Global CDMO Conference
9/27/2022
Avid Bioservices, Inc. today announced that the company will participate in the RBC Global CDMO Conference. Nick Green, president and chief executive officer, will be the featured speaker in a fireside chat at the conference, which will take place October 3-4, 2022.
-
Avid Bioservices Appoints Michael Alston, Jr. as Vice President, Operations
9/22/2022
Avid Bioservices, Inc. today announced the appointment of Michael Alston, Jr. as vice president, operations.
-
Avid Bioservices to Participate in Morgan Stanley 20th Annual Global Healthcare Conference
9/7/2022
Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that the company will participate in the Morgan Stanley 20th Annual Global Healthcare Conference.
-
Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2022 and Recent Developments
9/6/2022
Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced financial results for the first quarter ended July 31, 2022.
-
Biopharma and life sciences companies, such as Seraxis, Verily and Vaxart, tap new members to bolster their leadership teams in roles like CMO, CTO, CCO, and more.
-
Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2023 After Market Close on September 6, 2022
8/30/2022
Avid Bioservices, Inc. (NASDAQ:CDMO), today announced that it will report financial results for the first quarter of fiscal year 2023 on September 6, 2022 after market close and will host a webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time).
-
Avid Bioservices Reports Financial Results for Fourth Quarter and Full Fiscal Year Ended April 30, 2022 and Recent Developments
6/29/2022
Avid Bioservices, Inc. (NASDAQ:CDMO), today announced financial results for the fourth quarter and full fiscal year, ended April 30, 2022.
-
Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2022 After Market Close on June 29, 2022
6/22/2022
Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the quarter and fiscal year ended April 30, 2022 on June 29, 2022 after market close and will host a conference call and webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time).
-
Avid Bioservices, Inc. and CRB highlight efforts that enabled opening of first phase of new viral vector facility in California in only eight months
6/16/2022
Avid Bioservices, Inc., a dedicated contract development and manufacturing organization focused on development and CGMP manufacturing services for biotechnology and pharmaceutical companies, highlighted the companies' collaborative efforts that enabled the phase-one opening of its new purpose-built, 53,000-square-foot viral vector and CGMP facility in Costa Mesa, California, in only eight months.
-
Avid Bioservices Announces Launch of Analytical and Process Development Suites Within New, World-Class Viral Vector Development and Manufacturing Facility
6/14/2022
Avid Bioservices, Inc. today announced the opening of the analytical and process development (AD/PD) suites within the company’s new, world-class viral vector development and CGMP manufacturing facility.
-
Avid Bioservices Announces Further Expansion of Process Development Capacity for Mammalian Cell Business
6/13/2022
Avid Bioservices, Inc. today announced that the company is further expanding its process development capacity for its mammalian cell business.
-
Avid Bioservices to Participate in KeyBanc Capital Markets Life Sciences & MedTech Forum
3/16/2022
Avid Bioservices, Inc., a dedicated biologics contract development and manufacturing organization working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, announced that the company will participate in the KeyBanc Capital Markets Life Sciences & MedTech Forum.
-
Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2022 and Recent Developments
3/8/2022
Avid Bioservices, Inc. announced financial results for the third quarter of fiscal 2022, ended January 31, 2022.
-
Avid Bioservices to Report Financial Results for Third Quarter of Fiscal Year 2022 after Market Close on March 8, 2022
3/1/2022
Avid Bioservices, Inc. (NASDAQ:CDMO), today announced that it will report financial results for the third quarter of fiscal year 2022 on March 8, 2022 after market close and will host a conference call and webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time).
-
Avid Bioservices Announces Official Opening of Second Downstream Processing Suite Within Myford North Facility
1/10/2022
Avid Bioservices, Inc., a dedicated biologics contract development and manufacturing organization working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, announced the official opening of the second downstream processing suite within the company’s existing Myford North facility.
-
Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2021 and Recent Developments
12/7/2021
Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced financial results for the second quarter of fiscal 2022, ended October 31, 2021.
-
Avid Bioservices to Report Financial Results for Second Quarter of Fiscal Year 2022 After Market Close on December 7, 2021
11/30/2021
Avid Bioservices, Inc. (NASDAQ:CDMO), today announced that it will report financial results for the second quarter of fiscal year 2022 on December 7, 2021 after market close and will host a conference call and webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time).
-
Avid Bioservices Appoints Elie G. Hanania, Ph.D., as Vice President, Process Development, Viral Vector Technologies
11/4/2021
Avid Bioservices, Inc., a dedicated biologics contract development and manufacturing organization working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, announced the appointment of Elie G. Hanania, Ph.D., as vice president, process development, viral vector technologies.